Phase 2 N=102 KBP-201 COVID-19 Vaccine Trial in Healthy Volunteers
Covid19
Primary: Solicited Administration Site Reactions — 19; 15; 20 participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=100 Genotype-Directed Study Of Irinotecan Dosing In FOLFIRI + BevacizumabTreated Metastatic Colorectal Cancer
Colon Cancer
Primary: Progression Free Survival — 38; 34; 6; 3 Participants
Phase 2 N=28 An Open-Label Study of Oral NNZ-2591 in Pitt Hopkins Syndrome (PTHS-001)
Pitt Hopkins Syndrome
Primary: Safety and Tolerability — 15; 0; 4; 12 Participants
Phase 2 N=146 Study to Evaluate SAGE-324 in Participants With Essential Tremor
Essential Tremor
Primary: Change From Baseline in The Essential Tremor Rating Assessment Scale (TETRAS) Performance Subscale Item 4 (Upper Limb) Total Score on Day 91 in the Monotherapy Cohort…
Phase 2 N=13 AlloStim® Immunotherapy Dosing Alone or in Combination With Cryoablation in Metastatic Colorectal Cancer
Colorectal Cancer Metastatic
Primary: Evaluate the Overall Survival — 97; 368 days
Phase 2 N=239 18F-DCFPyL PET/CT Impact on Treatment Strategies for Patients With Prostate Cancer
Prostate Cancer
Primary: PRIMARY OBJECTIVES: I. To Determine the Impact of 18F-DCFPyL PET/CT on Initial and Subsequent Treatment Strategies of Patients With Prostate Cancer. — 66.2 Percent
Phase 2 N=106 Study of huCART19 for Very High-Risk (VHR) Subsets of Pediatric B-ALL
Acute Lymphoblastic Leukemia
Primary: Number of Subjects With Event-Free Survival in Patients With Newly Diagnosed VHR B-ALL or High-risk Relapse of B-ALL 1 Year After Treatment. — 68.9 percentage of subjects
Phase 2 N=11 Dendritic Cell Therapy, Cryosurgery, and Pembrolizumab in Treating Patients With Non-Hodgkin Lymphoma
Aggressive Non-Hodgkin Lymphoma · Indolent Non-Hodgkin Lymphoma · Recurrent Diffuse Large B-Cell Lymphoma
Primary: Number of Patients That Experienced a Dose Limiting Toxicity (DLT) — 0 Participants
Phase 2 N=200 Sustained Acoustic Medicine (SAM) for Symptomatic Treatment of Knee Pain Related to Osteoarthritis
Osteo Arthritis Knee · Arthritis
Primary: Change in Pain Units on a Scale (0-10) 0 Being Least, 10 Being Worst Pain (Value at 8 Weeks Minus Value at Baseline). — -3.7; -3.02; -1.61 units on a scale
Phase 2 N=197 A Biomarker-Guided, Randomized, Placebo-Controlled Efficacy and Safety Study of Liafensine in Patients With TRD
Treatment Resistant Depression
Primary: Change in Montgomery Åsberg Depression Rating Scale (MADRS) Total Score From Baseline to Day 42, in DGM4-positive Patients — -15.4; -15.5; -15.4; -11.0 Units on a Scale…
Phase 2 N=82 A Study of Brentuximab Vedotin and CHP in Frontline Treatment of PTCL With Less Than 10% CD30 Expression
Peripheral T-cell Lymphoma
Primary: Objective Response Rate (ORR) Per Blinded Independent Central Review (BICR) by Revised Response Criteria for Malignant Lymphoma Criteria (Cheson 2007) by Central CD30…
Phase 2 N=86 SIKAMIC (SIklos on Kidney Function and AlbuMInuria Clinical Trial)
Sickle Cell Disease
Primary: Number of Patients Achieving at Least a 30% Decrease in ACR Baseline Value — 18; 15 Participants
Phase 2 N=108 REC 0/0559 Eye Drops for Treatment of Moderate and Severe Neurotrophic Keratitis in Adult Patients
Neurotrophic Keratitis
Primary: Corneal Healing — 4; 2; 1; 2 Participants
Phase 2 N=19 Venetoclax, Carmustine, Etoposide, Cytarabine, and Melphalan Before Stem Cell Transplant in Treating Participants With Relapsed or Refractory Non-Hodgkin Lymphoma
Hematopoietic Cell Transplantation Recipient · Recurrent Diffuse Large B-Cell Lymphoma · Recurrent Grade 1 Follicular Lymphoma
Primary: Maximum Tolerated Dose of Venetoclax Defined to be the Dose Cohort Below Which 3 Out of 6 Patients Experience Dose Limiting Toxicities or the Highest Dose Cohort of 1200…
Phase 2 N=65 Multiple Ascending Dose Safety, Tolerability, PK Study of AL001 in Alzheimer's Disease Patients & Healthy Adult Subjects
Alzheimer's Disease · Healthy Non-elderly and Elderly Adults
Primary: Number of Participants With Serious AEs, TEAEs That Lead to Premature Discontinuation, Abnormal Laboratory Test Results, Abnormal ECG Readings. — 0; 0; 0; 0 Participants